This text can be freely obtainable to view in March 2022. Labiotech members have unique entry earlier than it’s unlocked.
Viral an infection therapies, cell remedy, and synthetic intelligence led biotech investments in January 2022 because the European sector took a collective breather from December’s funding frenzy.
European biotech investments began 2022 at a modest stage in comparison with the massive money move seen in November and December 2021. Whereas December 2021 noticed virtually €1.6B cash raised, January’s complete hit €660M in 41 offers. These included non-public investments and preliminary public choices going to life sciences firms in Europe and Israel.
Non-public biotech investments drove almost all of January’s funding; the UK agency Genflow Biosciences launched the one biotech IPO, elevating €4.4M on the London Inventory Change. The agency challenged a stormy biotech inventory market, which has triggered headwinds for biotech IPO hopefuls in the previous couple of months.
Industrial biotech firms particularly noticed a plunge in investments in January.
This content material is on the market completely to our paying members.
Our members obtain the next advantages:
- Unlock premium articles
- Obtain our business experiences
- Take away all banner adverts
- Entry 1,500+ archived posts
- Assist our unbiased media
